|View printer-friendly version|
|October 16, 2002 4:21 p.m.|
|Copaxone® Approved for Seven Days Room Temperature Storage in 16 European Countries|
Makes treatment more convenient for Multiple Sclerosis patients
Jerusalem, Israel, October 16, 2002 - Teva Pharmaceutical Industries, Ltd., (NASDSQ: TEVA) and Aventis (NYSE: AVE), announced that the application for seven days room temperature storage of Copaxone® (glatiramer acetate) has been approved across sixteen European countries. As Copaxone® can now be kept unrefrigerated for this period, it offers greater convenience for patients.